Clovis Oncology Stock Price, News & Analysis (NASDAQ:CLVS)

$64.13 -0.01 (-0.02 %)
(As of 12/17/2017 12:41 PM ET)
Previous Close$64.13
Today's Range$63.00 - $65.40
52-Week Range$36.40 - $99.45
Volume1.88 million shs
Average Volume1.10 million shs
Market Capitalization$3.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000

Debt

Debt-to-Equity Ratio0.94%
Current Ratio3.19%
Quick Ratio3.16%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$80,000.00
Price / Sales39,287.64
Cash FlowN/A
Price / CashN/A
Book Value($0.08) per share
Price / Book-801.63

Profitability

Trailing EPS($8.28)
Net Income$-349,130,000.00
Net Margins-947.47%
Return on Equity-122.06%
Return on Assets-38.84%

Miscellaneous

Employees278
Outstanding Shares49,010,000

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology, Inc. (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.18) by $0.06. The biopharmaceutical company had revenue of $16.81 million for the quarter, compared to analysts' expectations of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same quarter last year, the company earned ($1.70) earnings per share. View Clovis Oncology's Earnings History.

When will Clovis Oncology make its next earnings announcement?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for Clovis Oncology.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

18 equities research analysts have issued 1 year price objectives for Clovis Oncology's stock. Their forecasts range from $38.00 to $125.00. On average, they expect Clovis Oncology's share price to reach $85.47 in the next year. View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. According to Zacks Investment Research, "Clovis’ Rubraca registered impressive sales in the second quarter. The FDA’s accelerated approval to ovarian cancer treatment, Rubraca in Dec 2016 was a huge boost for  the company. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on achieving continued approval for the drug. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study in Jun 2017 are positives. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have outperformed the industry so far this year. Loss Estimates have narrowed ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters." (10/17/2017)
  • 2. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)
  • 3. Goldman Sachs Group Inc analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board (Age 74)
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director (Age 54)
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer (Age 54)
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer (Age 63)
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer (Age 49)
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer (Age 50)
  • Brian G. Atwood, Independent Director (Age 64)
  • James C. Blair Ph.D., Independent Director (Age 77)
  • Keith T. Flaherty M.D., Independent Director (Age 46)
  • Ginger L. Graham, Independent Director (Age 62)

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (4.87%), Jennison Associates LLC (1.22%), Macquarie Group Ltd. (1.08%), Westfield Capital Management Co. LP (0.94%), Pictet Asset Management Ltd. (0.75%) and Emerald Advisers Inc. PA (0.68%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Wells Fargo & Company MN, Janus Henderson Group PLC, Crawford Lake Capital Management LLC, Canada Pension Plan Investment Board, Chicago Equity Partners LLC, Asymmetry Capital Management L.P. and TD Asset Management Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sectoral Asset Management Inc, Macquarie Group Ltd., Sector Gamma AS, Westfield Capital Management Co. LP, Frontier Capital Management Co. LLC, Columbus Circle Investors and Artal Group S.A.. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $64.13.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $3.14 billion and generates $80,000.00 in revenue each year. The biopharmaceutical company earns $-349,130,000.00 in net income (profit) each year or ($8.28) on an earnings per share basis. Clovis Oncology employs 278 workers across the globe.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (CLVS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  632
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Clovis Oncology (NASDAQ:CLVS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.582.582.562.69
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $79.71$79.71$79.63$74.54
Price Target Upside: 21.71% upside21.71% upside3.76% upside15.18% downside

Clovis Oncology (NASDAQ:CLVS) Consensus Price Target History

Price Target History for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ:CLVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Leerink SwannReiterated RatingOutperform$107.00 -> $90.00N/AView Rating Details
11/3/2017Stifel NicolausReiterated RatingBuy$125.00N/AView Rating Details
11/2/2017Morgan StanleyLower Price TargetOverweight$89.00 -> $86.00N/AView Rating Details
10/23/2017BarclaysInitiated CoverageOverweight -> Overweight$105.00N/AView Rating Details
10/10/2017OppenheimerReiterated RatingHoldN/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$81.00LowView Rating Details
9/11/2017CannReiterated RatingHoldLowView Rating Details
8/18/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$73.00HighView Rating Details
8/3/2017Bank of AmericaReiterated RatingBuyLowView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetBuy$107.00LowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$125.00HighView Rating Details
6/22/2017SunTrust BanksReiterated RatingBuyLowView Rating Details
6/20/2017Goldman Sachs GroupReiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Clovis Oncology (NASDAQ:CLVS) Earnings History and Estimates Chart

Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ CLVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018($1.29)N/AView Earnings Details
11/1/2017Q3 2017($1.18)($1.24)$21.12 million$16.81 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.27)($1.29)$13.07 million$14.62 millionViewListenView Earnings Details
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Clovis Oncology (NASDAQ:CLVS) Earnings Estimates

2017 EPS Consensus Estimate: ($5.16)
2018 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20173($1.30)($1.18)($1.23)
Q3 20173($1.24)($1.10)($1.15)
Q4 20173($1.31)($1.23)($1.26)
Q1 20182($1.38)($1.16)($1.27)
Q2 20182($1.01)($0.68)($0.85)
Q3 20182($0.64)($0.46)($0.55)
Q4 20182($0.17)($0.08)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Clovis Oncology (NASDAQ:CLVS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Clovis Oncology (NASDAQ CLVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.50%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology (NASDAQ CLVS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Thorlef SpickschenDirectorSell4,500$60.00$270,000.00View SEC Filing  
11/15/2017Gillian C Ivers-ReadInsiderSell3,000$63.70$191,100.00View SEC Filing  
10/16/2017Gillian C Ivers-ReadInsiderSell3,000$84.54$253,620.00View SEC Filing  
9/15/2017Gillian C Ivers-ReadInsiderSell3,000$69.50$208,500.00View SEC Filing  
8/15/2017Gillian C Ivers-ReadInsiderSell3,000$70.05$210,150.00View SEC Filing  
8/4/2017James C BlairDirectorSell18,450$78.61$1,450,354.50View SEC Filing  
7/17/2017Gillian C Ivers-ReadInsiderSell3,000$91.56$274,680.00View SEC Filing  
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Clovis Oncology (NASDAQ CLVS) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million Brokerages Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million
www.americanbankingnews.com - December 16 at 6:32 AM
Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key ThresholdClovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold
finance.yahoo.com - December 15 at 5:40 PM
 Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.27 Per Share Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.27 Per Share
www.americanbankingnews.com - December 14 at 11:02 PM
Noteworthy Wednesday Option Activity: FNSR, CLVS, UAANoteworthy Wednesday Option Activity: FNSR, CLVS, UAA
www.nasdaq.com - December 13 at 5:16 PM
Value Biotech ETFs to Buy NowValue Biotech ETFs to Buy Now
finance.yahoo.com - December 13 at 5:16 PM
Clovis Oncology (CLVS) Lifted to "Sell" at BidaskClubClovis Oncology (CLVS) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - December 9 at 9:50 AM
Clovis Oncology, Inc. (CLVS) Director Sells $270,000.00 in StockClovis Oncology, Inc. (CLVS) Director Sells $270,000.00 in Stock
www.americanbankingnews.com - December 8 at 11:16 PM
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drugClovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
finance.yahoo.com - December 6 at 9:55 AM
Clovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech MoversClovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech Movers
finance.yahoo.com - December 6 at 9:55 AM
ValuEngine Lowers Clovis Oncology (CLVS) to SellValuEngine Lowers Clovis Oncology (CLVS) to Sell
www.americanbankingnews.com - December 5 at 10:50 PM
Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug ApplicationClovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
finance.yahoo.com - December 5 at 5:03 PM
Clovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from AnalystsClovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 4 at 9:41 AM
Commit To Purchase Clovis Oncology At $40, Earn 14.2% Using OptionsCommit To Purchase Clovis Oncology At $40, Earn 14.2% Using Options
www.nasdaq.com - November 28 at 5:06 PM
 Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $20.02 Million
www.americanbankingnews.com - November 28 at 3:50 AM
Zacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Announce -$1.27 EPSZacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Announce -$1.27 EPS
www.americanbankingnews.com - November 26 at 7:32 PM
Clovis Oncology Stock Pullback Offers Opportunity With Strong Q3 NumbersClovis Oncology Stock Pullback Offers Opportunity With Strong Q3 Numbers
seekingalpha.com - November 24 at 3:56 PM
3 Companies Competing to Gain Lead in Ovarian Cancer Market3 Companies Competing to Gain Lead in Ovarian Cancer Market
www.zacks.com - November 24 at 11:09 AM
Today’s Research Reports on Trending Tickers: Ekso Bionics and Clovis OncologyToday’s Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology
finance.yahoo.com - November 20 at 6:23 PM
Leerink Swann Reiterates "Outperform" Rating for Clovis Oncology, Inc. (CLVS)Leerink Swann Reiterates "Outperform" Rating for Clovis Oncology, Inc. (CLVS)
www.americanbankingnews.com - November 19 at 6:20 PM
Leerink Swann Comments on Clovis Oncology, Inc.s FY2018 Earnings (CLVS)Leerink Swann Comments on Clovis Oncology, Inc.'s FY2018 Earnings (CLVS)
www.americanbankingnews.com - November 18 at 9:38 AM
Oversold Conditions For Clovis Oncology (CLVS)Oversold Conditions For Clovis Oncology (CLVS)
www.nasdaq.com - November 18 at 8:40 AM
Clovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 SharesClovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares
www.americanbankingnews.com - November 16 at 8:37 PM
Notable Friday Option Activity: ICPT, GILD, CLVSNotable Friday Option Activity: ICPT, GILD, CLVS
www.nasdaq.com - November 10 at 5:04 PM
Clovis Oncology to Present at the Stifel 2017 Healthcare Conference - Business Wire (press release)Clovis Oncology to Present at the Stifel 2017 Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 10 at 9:49 AM
Clovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from AnalystsClovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 9 at 10:16 AM
Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017
finance.yahoo.com - November 8 at 9:17 PM
Clovis Oncology to Present at the Stifel 2017 Healthcare ConferenceClovis Oncology to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 9:17 PM
Q4 2017 Earnings Forecast for Clovis Oncology, Inc. Issued By Oppenheimer Holdings (CLVS)Q4 2017 Earnings Forecast for Clovis Oncology, Inc. Issued By Oppenheimer Holdings (CLVS)
www.americanbankingnews.com - November 8 at 4:32 PM
Clovis Oncology, Inc. (CLVS) to Post Q4 2017 Earnings of ($1.23) Per Share, Oppenheimer Holdings ForecastsClovis Oncology, Inc. (CLVS) to Post Q4 2017 Earnings of ($1.23) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - November 6 at 9:38 AM
Gabelli Brokers Boost Earnings Estimates for Clovis Oncology, Inc. (CLVS)Gabelli Brokers Boost Earnings Estimates for Clovis Oncology, Inc. (CLVS)
www.americanbankingnews.com - November 6 at 6:36 AM
FY2017 EPS Estimates for Clovis Oncology, Inc. Lowered by Analyst (CLVS)FY2017 EPS Estimates for Clovis Oncology, Inc. Lowered by Analyst (CLVS)
www.americanbankingnews.com - November 6 at 6:36 AM
SunTrust Banks Weighs in on Clovis Oncology, Inc.s FY2017 Earnings (CLVS)SunTrust Banks Weighs in on Clovis Oncology, Inc.'s FY2017 Earnings (CLVS)
www.americanbankingnews.com - November 6 at 6:36 AM
Clovis Oncologys (CLVS) Buy Rating Reiterated at Stifel NicolausClovis Oncology's (CLVS) Buy Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - November 4 at 6:42 PM
Notable Thursday Option Activity: CLVS, GOGO, ENDPNotable Thursday Option Activity: CLVS, GOGO, ENDP
www.thestreet.com - November 2 at 6:07 PM
Edited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 6:06 PM
Clovis reports 3Q lossClovis reports 3Q loss
finance.yahoo.com - November 1 at 11:08 PM
Clovis Oncology Announces Third Quarter 2017 Operating Results - Business Wire (press release)Clovis Oncology Announces Third Quarter 2017 Operating Results - Business Wire (press release)
www.businesswire.com - November 1 at 6:05 PM
Clovis Oncology, Inc. to Host Earnings CallClovis Oncology, Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 6:05 PM
Clovis Oncology Announces Third Quarter 2017 Operating ResultsClovis Oncology Announces Third Quarter 2017 Operating Results
finance.yahoo.com - November 1 at 6:05 PM
Neurocrine, Exelixis, Juno Stocks Rocket After Crushing ViewsNeurocrine, Exelixis, Juno Stocks Rocket After Crushing Views
finance.yahoo.com - November 1 at 6:05 PM
Clovis Oncology, Inc. (CLVS) Issues Quarterly  Earnings ResultsClovis Oncology, Inc. (CLVS) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 1 at 5:46 PM
Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?
www.nasdaq.com - October 30 at 4:02 PM
MGNX Soars On INCY Deal, CDTX Strides Ahead, NUVA Entices, ACHC In Poor HealthMGNX Soars On INCY Deal, CDTX Strides Ahead, NUVA Entices, ACHC In Poor Health
www.nasdaq.com - October 25 at 11:52 PM
Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : October 25, 2017Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : October 25, 2017
finance.yahoo.com - October 25 at 6:49 PM
Clovis Oncology, Inc. (CLVS) Set to Announce Earnings on WednesdayClovis Oncology, Inc. (CLVS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017
finance.yahoo.com - October 24 at 7:40 PM
Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1
finance.yahoo.com - October 23 at 5:53 PM
Clovis Oncology, Inc. (CLVS) Expected to Post Quarterly Sales of $20.46 MillionClovis Oncology, Inc. (CLVS) Expected to Post Quarterly Sales of $20.46 Million
www.americanbankingnews.com - October 21 at 8:14 AM
Zacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Post -$1.16 EPSZacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Post -$1.16 EPS
www.americanbankingnews.com - October 19 at 8:19 AM
Insider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of StockInsider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - October 17 at 10:20 PM

SEC Filings

Clovis Oncology (NASDAQ:CLVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Clovis Oncology (NASDAQ:CLVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Clovis Oncology (NASDAQ CLVS) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.